Company Overview of KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, primarily develops monoclonal antibody therapeutics for the treatment of respiratory diseases and cancer in the United States. Its product candidates include KB001-A, which is in a Phase II clinical trial for the prevention and treatment of pseudomonas aeruginosa infection in mechanically ventilated and cystic fibrosis patients; KB003 that is in a Phase II clinical trial for the treatment of inflammatory diseases; and KB004, which is in a Phase I clinical trial for the treatment of hematologic malignancies and solid tumors. The company has a collaboration agreement with Sanofi Pasteur S.A. for the development of KB001-A. KaloBios P...
260 East Grand Avenue
South San Francisco, CA 94080
Founded in 2000
Key Executives for KaloBios Pharmaceuticals, Inc.
Chief Executive Officer
Total Annual Compensation: $417.5K
Chief Medical Officer
Total Annual Compensation: $410.0K
Chief Scientific Officer and Executive Vice President of Research & Development
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2013.
KaloBios Pharmaceuticals, Inc. Key Developments
KaloBios Pharmaceuticals, Inc.(NasdaqGM:KBIO) dropped from Russell 2000 Index
Jun 30 14
KaloBios Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.
KaloBios Pharmaceuticals, Inc.(NasdaqGM:KBIO) dropped from Russell 3000 Index
Jun 30 14
KaloBios Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.
KaloBios Pharmaceuticals, Inc. Approves an Amendment to the Amended and Restated Certificate of Incorporation
Jun 20 14
KaloBios Pharmaceuticals, Inc. approved an amendment to the company's amended and restated certificate of incorporation to increase the authorized number of shares of common stock from 47,500,000 shares to 85,000,000 shares at its AGM held on June 18, 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries